Table 1.

Patient characteristics by IL-1α Immunostaining.

		Nuclear IL-1α∗				Cytoplasmic IL-1α∗
Characteristics	Total (n)	2 (%)	1 (%)	0 (%)	p-value	2 (%)	1 (%)	0 (%)	p-value
Number of Evaluable	141
Subjects
Sex
Male	82	57	58	57	0.99	50	58	59	0.37
Female	59	43	42	43		50	42	41
Avg Age at Diagnosis
Male	58	59	58	54	0.74	53	57	62	0.28
(avg (range))	(31-81)	(37-76)	(31-81)	(44-69)			(31-81)	(37-73)
Female	66	58	68	63		78	67	61
(avg (range))	(19-33)	(19-81)	(20-93)	(58-73)			(19-93)	(44-80)
Smoking History
Active Smoker	56	36	42	29	<0.0001	0	39	44	<0.0001
Never Smoker	49	29	38	14		100	34	33
Quit <10 Years	13	14	7	29		0	9	11
Quit >10 Years	17	11	11	29		0	13	11
Tobacco Chewer	6	11	3	0		0	5	0
Tumor Site
Alveolus	21	7	18	0	<0.0001	50	13	19	<0.0001
Floor of the Mouth	31	18	23	29		0	17	44
Oral Tongue	54	46	37	29		0	44	19
Other	35	29	23	43		50	26	19
T Stage
T1	42	36	29	14	0.001	50	30	26	<0.00001
T2	42	36	28	29		0	30	30
T3/T4	57	29	42	57		50	39	44
N Stage
N0	74	43	56	43	0.137	50	54	48	<0.00001
N1/2a	27	29	16	29		0	16	33
N2b/2c/3	40	29	28	29		50	30	19
Differentiation
well	17	7	13	14	<0.001	0	13	7	<0.0001
moderate	90	75	62	43		50	64	63
poor	34	18	25	43		50	22	30
Perineural Invasion
Yes	69	61	45	57	0.06	0	50	48	<0.001
No	72	39	55	43		100	50	52
Lymphovascular Invasion
Yes	52	43	35	43	0.41	50	39	26	0.002
No	89	57	65	57		50	61	74
Bone Invasion
Yes	42	21	68	29	<0.001	50	29	30	0.002
No	99	79	32	71		50	71	70
Radiotherapy
Yes	78	57	54	71	0.032	100	53	63	<0.00001
No	63	43	46	29		0	47	37
Chemotherapy
Yes	22	14	15	29	0.011	50	15	15	<0.00001
No	119	86	85	71		50	85	85

∗Percentages may not sum to 100% due to rounding.